Oats (Avena sativa L.) are a nutritionally valuable cereal crop known for their unique profile of bioactive compounds, including protein, β-glucan (BG), and avenanthramides (AVNs). However, industrial-scale processing and fractionation of these nutrients at an industrial scale are restricted by high oil content, limiting their application as functional food ingredients. While reducing oil content through targeted breeding may overcome these barriers, this strategy requires a deeper molecular understanding of lipid metabolism and its interplay with other nutrient pathways. In this review, we highlight the health benefits of key oat nutrients and discuss challenges in isolation techniques at an industrial scale. We then outline the canonical pathway for seed oil biosynthesis, supported by functional validation of genes encoding key lipid synthesis enzymes, and review studies linking regulatory enzymes to variations in oat oil content at gene and transcript levels. Finally, we highlight how mass spectrometry-based omics, particularly proteomics and lipidomics, can be used in breeding programmes to elucidate regulatory networks involved in oat oil biosynthesis and nutrient partitioning at the phenotype level.
Commercial lactoferrin is extracted from bovine milk using cation exchange chromatography with agarose-based Sepharose SP Big Beads. After over a thousand cycles, the column must be replaced due to backpressure exceeding operational limits. This increase in backpressure was not caused by fouling as previously thought but structural degradation of the agarose beads. Internal porosity increased from 0.78 to 0.86, indicating backbone depletion. The beads lose mechanical strength and compress during operation, which increases the backpressure and ultimately cause bed collapse. This structural damage was clearly visible in scanning electron microscopy. Compared to fresh resin, used beads showed a decrease in median particle size (175.20 ± 6.56 µm to 170.88 ± 0.16 µm) and pore size (peak location of log normal pore size distribution: 9.24 ± 0.091 nm to 8.43 ± 0.100 nm). While equilibrium binding capacity remained stable, ionic capacity declined by 23%, and dynamic binding capacity increased by 31%. This increase in dynamic binding capacity can be explained by the smaller particle size and higher intraparticle porosity, which both enhance mass transfer, while the slight reduction in pore size has a negligible effect. FTIR and Raman spectroscopy confirmed chemical changes in the agarose structure. No agarose-degrading enzymes were detected in milk, but exposing fresh beads to cleaning agents (NaOH, acetic acid, NaClO) replicated the chemical changes observed in used resin, demonstrating that the cleaning-in-place (CIP) treatment degrades the agarose backbone over time, leading to a loss in ligands, leaching of the backbone, and ultimately a mechanically weaker resin.
11 May 2026 in Analytical and Bioanalytical Chemistry
The metabolic architecture of oat grains remains poorly understood at the cellular and proteome levels despite increasing interest for applications such as nutritional enhancement and functional crop improvement. In this study, we performed matrix-assisted laser desorption and ionization mass spectrometry imaging (MALDI-MSI) to map metabolite distributions across oat grain tissues and delineate major compartments of metabolite localization. These metabolite-rich regions, notably the bran, endosperm, and embryo, were then isolated for proteomic analysis, which detected around 3700 proteins across all tissue types. Gene ontology analysis highlighted specialized functions and biological processes associated with each compartment. Further interrogation of key proteins revealed the enrichment of core cellular functions such as energy generation, translation, and stress resilience in the embryo, nutrient storage in the endosperm, and an intermediate functional profile in the bran. These findings provide new insights into the spatial organization of metabolic functions within oat grains and warrant further exploration of sub-regions for a deeper understanding of the oat metabolic architecture. Graphical Abstract
25 September 2025 in Journal of Genetic Engineering and Biotechnology
Giardia lamblia is a globally prevalent protozoan responsible for Giardiasis, an intestinal disease commonly treated with nitroimidazoles such as metronidazole, tinidazole, and albendazole. However, increasing drug resistance has reduced treatment efficacy. Rho GTPase and its regulator, putative Rho GTPase-activating protein (RhoGAP), play crucial roles in Giardia's encystation, membrane trafficking, and metabolism. This study explores these proteins as potential drug targets. We employed sequence-based target prediction, molecular docking, molecular dynamics (MD) simulations, minimal inhibitory concentration (MIC) assays, and label-free quantitative proteomics (LFQ) to identify and validate potential inhibitors. Target sequence analysis revealed Dextromethorphan and Azathioprine as candidate Rho GTPase inhibitors, and Imatinib, Dasatinib, and Ponatinib as RhoGAP inhibitors. Molecular docking using AutoDock Vina yielded binding energies ranging from -5.3 to -8.5 kcal/mol. MD simulations via GROMACS confirmed structural compactness and complex stability. In vitro MIC assays demonstrated that Dasatinib and Imatinib inhibited RhoGAP at concentrations of 12.5 µM and 100 µM, respectively, while azathioprine inhibited Rho GTPase at 500 µM. Dextromethorphan showed no inhibitory activity. LFQ proteomic analysis further confirmed Dasatinib's significant impact on protein expression profiles. These findings highlight RhoGAP as a promising therapeutic target in G. lamblia, with Dasatinib showing potential as a repurposed treatment for Giardiasis. Proteomic data are publicly available in the MASSIVE database under identifier MSV000097321.
Ovarian cancer diagnosis is often delayed due to poorly defined clinical symptoms, underscoring the need for novel biomarkers that enable earlier detection. Protein biomarker discovery in blood samples is analytically challenging using mass spectrometry, as high‐abundance proteins can obscure detection of low‐abundance biomarkers. Ovarian vein (ovarian) and median cubital vein (peripheral) serum were collected from healthy women or patients with benign or malignant (majority stage I) serous ovarian tumours. Proteograph XT assay was employed as a protein enrichment methodology prior to LC–MS/MS analyses to obtain deeper proteome coverage in these samples. From an initial cohort of 53 samples, we identified 6603 proteins across all samples, including 3467 proteins uniquely identified in ovarian serum. Following exclusion of red blood cell–contaminated samples, differential abundance analysis identified 86 and 101 malignancy‐associated protein candidates in ovarian and peripheral samples, respectively. Notably, ANK1, CAND1 and GMPR2 were differentially abundant across both sample types. Using logistic regression with repeated cross‐validation and permutation testing, ANK1 demonstrated strong discriminatory performance [area under the curve (AUC) = 0.97] when combined with clinical CA125 measurements. These findings highlight the importance of ovarian vein sampling for enhanced access to tumour‐associated proteins and support further validation of these candidate biomarkers for early ovarian cancer detection.